While lower price cards can help ease the stress of superior drug charges during the temporary, they do not tackle the systemic problems driving up prescription prices while in the U.S. Broader plan variations could deal with the basis leads to of growing drug rates, like lack of transparency in pricing and also the role of intermediaries like PBMs